TCR2 Therapeutics Inc. announced it has entered into a Cooperative Research and Development Agreement with NCI to collaborate on the use of TCR2’s proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in the Company’s ongoing phase I/II trial of TC-210.
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
